Whalesbook
Toh dosto, baat karte hain OneSource Specialty Pharma ki. Aapne suna hoga GLP-1 drugs ke baare mein, jaise Ozempic wagera? Yeh market abhi $67 billion se bhi bada hai aur 2026 mein toh jaise explosion aane wala hai! Kyunki kai bade drugs ke patents expire ho rahe hain, jisse Contract Manufacturing organizations (CDMOs) ke liye $1-2 billion ka naya business ban sakta hai.
OneSource ismein ekdum sahi position par hai. Yeh company complex drug-device combinations (DDCs), jaise GLP-1 injection pens, banane mein expert hai. Inka Bengaluru wala facility USFDA approved hai aur wahan biologics fill-finish aur device assembly dono hota hai, jo India mein badi baat hai. Abhi haal hi mein inhone Dr. Reddy's ke generic Semaglutide Injection (Ozempic ka alternative) ke liye CDMO partner ke taur par kaam kiya hai, jise Health Canada se approval mila hai. Aur bhi aise approvals aa rahe hain alag alag markets mein. Company apni cartridge capacity ko 40 million units se badha kar 220 million karne jaa rahi hai FY27 tak, jiske liye 20 se zyada GLP-1 customers ke saath long-term deals hain. Management ka kehna hai ki FY28 tak revenue $500 million aur EBITDA margin 40% tak pahunch jayega. Yeh FY25 ke $170 million revenue se kaafi bada jump hoga.
Lekin, yahan ek bada sawaal hai – kya yeh sab valuation ko justify karta hai? OneSource ka market cap abhi lagbhag ₹20,000-₹21,000 crore hai. Iska trailing Price-to-Earnings (P/E) ratio 120x se upar, kabhi kabhi toh 1000x tak bhi chala jata hai! Compare karein toh Syngene International ka P/E 57-58x hai aur Divi's Laboratories ka 71-72x. Asian Life Sciences industry ka average toh sirf 37.7x hai. Matlab, market is company se future mein dher saara growth expect kar raha hai. Agar FY28 ki projections dekhein toh revenue ₹4,200 crore aur 40% EBITDA margin se, EV/EBITDA 12x ke aas paas aata hai, jo compare karne layak hai. Global CDMO market bhi badh raha hai, aur Asia Pacific sabse tez growth region hai. Toh thoda premium justified hai, par current P/E bahut stretched lag raha hai.
Ab baat karte hain risks ki. Itna bada growth target achieve karna aasan nahi hai. Recent reports ke mutabik, FY26 ke liye revenue estimates 24% kam ho gaye hain aur pichle hafte stock 17% gira bhi hai. Sabse badi chinta Q3 FY26 mein EBITDA margin ka 6% tak gir jaana hai, jo pichle saal 36% tha! Haalanki Q2 mein yeh 28% tha, par itna bada drop operational issues ka sanket de sakta hai. Pichle 3 saal mein profit growth flat raha hai aur ROE/ROCE negative. Company ke paas kuch hi bade customers hain, unse revenue tied hai. Aur haan, Prestige Biopharma ke saath $136.32 million ka arbitration case bhi chal raha hai. Agar GLP-1 therapies oral hone lagi toh company ka drug-device business affect ho sakta hai. Itna high P/E ka matlab hai ki future ki success pehle se hi stock price mein add ho chuki hai, jisse galti ki koi gunjaish nahi bachti.
Analysts abhi bhi mostly positive hain, consensus 'Buy' rating hai aur price targets ₹1,900s mein hain, jo current price se upar hai. Par kuch analysts ne haal hi mein price targets kam kiye hain aur FY26 revenue estimates bhi ghataaye hain. Company ke liye FY28 tak apne aggressive targets pura karna critical hoga. Agle 12-24 mahine bahut important honge yeh decide karne ke liye ki OneSource apne market position ko sustained performance mein badal payega ya nahi.